Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595379 | 1.00 | CYP1A2 (0.65) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL598737 | 0.91 | CYP1A2 (0.59) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL598688 | 0.82 | CYP1A2 (0.68) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL28046445 | 0.81 | CYP1A2 (0.50) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL424167 | 0.81 | CYP1A2 (1.00) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL29463284 | 0.81 | CYP1A2 (1.00) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL28942909 | 0.79 | HTT (0.52) | CYP1A2CYP2A6ALDH1A1HSD17B10ACHE | |
| SCHEMBL5083260 | 0.79 | CYP1A2 (0.48) | CYP1A2CYP2A6HPGDHSD17B10RAPGEF4 | |
| SCHEMBL9638708 | 0.79 | CYP1A2 (0.50) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL30365067 | 0.79 | CYP1A2 (0.48) | CYP1A2CYP2A6HPGDHSD17B10RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114433214-B | Composite carrier and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-114433214-A | Composite carrier and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-9739125-B2 | Method for upgrading in situ heavy oil | CHEVRON U.S.A. INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160177691-A1 | METHOD FOR UPGRADING IN SITU HEAVY OIL | CHEVRON U.S.A. INC. | 2016-06-23 | — | — | US | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1569652-A4 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2002005646-A2 | COMPOSITIONS FOR REPELLING CRAWLING INSECTS | S.C. JOHNSON & SON, INC. (US) (US) | 2002-01-24 | — | — | WO | disclosed |
| US-5756730-A | Process for preparing analgesic compounds | SANKYO COMPANY, LIMITED (JP) | 1998-05-26 | — | — | US | disclosed |
| US-5656758-A | AMIDATION OF AN AMINE-CONTAINING THIOMORPHOLINE OR PIPERAZINE COMPOUND | SANKYO COMPANY, LIMITED (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5512567-A | KAPPA-RECEPTOR AGONISTS | SANKYO COMPANY, LIMITED (JP) | 1996-04-30 | — | — | US | disclosed |
| US-5270327-A | Piperidine derivatives | SANKYO COMPANY, LIMITED (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0356247-B1 | ANALGESIC CARBOXYLIC ACID AMIDE DERIVATIVES | Sankyo Company Limited (JP) | 1993-03-17 | — | — | EP | disclosed |
| US-5030784-A | Process for converting lower-alkyl substituted aromatic compounds and butadiene to 4-aryl-1-butene or 4-aryl-1-pentene and propylene | SHELL OIL COMPANY (US) | 1991-07-09 | — | — | US | disclosed |
| US-5021413-A | Analgesic thiomorpholins their preparation, and pharmaceutical compositions containing them | SANKYO COMPANY LIMITED (JP) | 1991-06-04 | — | — | US | disclosed |
| EP-0356247-A1 | Analgesic carboxylic acid amide derivatives | Sankyo Company Limited (JP) | 1990-02-28 | — | — | EP | disclosed |
| US-RE29459-E | CATALYTIC ISOMERIZATION | CHEVRON RESEARCH COMPANY (US) | 1977-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | CYP1A2 1240/4885CYP2A6 1327/4885ALDH1A1 2325/4885 |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | CYP1A2 1415/4885CYP2A6 1388/4885ALDH1A1 2300/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | CYP1A2 1174/4885CYP2A6 1296/4885ALDH1A1 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.